/

MTVA

MetaVia Inc.Pre-market

1.43−0.02 −1.38%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayPre-market 1.50 +4.90%

Open

1.52

Prev close

1.45

Day range

1.421.52

52-week range

0.966014.85

Volume

62.52K0.74×

Mkt cap

9.42M

P/E ttm

—

Fwd P/E

—

EPS ttm

-3.65

Div yield

0.00%

Earnings

—

From 52w high

−90.37%

Price Chart

Yahoo Finance · delayed

MTVAOct 13, 2026O 1.52H 1.52L 1.41C 1.43−0.02 (−1.38%)Vol 65.40K

SMA 501.58
SMA 2002.14

1Y change −86.88% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

MTVA MetaVia Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.38%
1 month: −13.86%
3 months: −25.91%
6 months: −4.03%
Year to date: −83.02%
1 year: −86.88%

Valuation & ownership

Market cap: 9.42M
Enterprise value: −3.04M
P/E (ttm): —
Forward P/E: —
PEG ratio: —
Price / book: 1.38
Price / sales (ttm): —
EV / EBITDA: 0.20
EPS (ttm): -3.65
EPS (forward): —
Beta (5y monthly): 0.96
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 6.59M
Float: 4.80M
Short % of float: 2.44%
Short ratio (days): 1.36
Held by insiders: 28.61%
Held by institutions: 13.87%
Avg volume (3m): 85.06K
50-day average: 1.58
200-day average: 2.18
52-week change: −86.88%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 39.2
vs 50-day SMA: −9.30%
vs 200-day SMA: −33.05%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.47%
Realised vol (20d, ann.): 59.9%
From 52-week high: −90.37%
From 52-week low: +48.03%

ANR

Analyst Consensus

3 analysts

Consensus

—

Mean target

19.33

+1,251.98% implied

Low 8.00Median 20.00High 30.00

Recommendation trend

Now2 / 0 / 0
1m ago2 / 0 / 0
2m ago

DES

About MetaVia Inc.

Yahoo Finance profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 8
Headquarters: Cambridge, MA, United States
Website: metaviatx.com
Officers: Mr. Hyung Heon Kim CEO, President & Director

SEAS

Seasonality · MTVA

2016–2026 · monthly returns

Strongest month Jun +9.06%Weakest month Aug −18.99%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-71.1	-37.9	-20.5	20.0	97.2	-49.6	-0.7	21.1	-8.7	-8.9			−83.0%
2025	-10.8	-19.3	5.5	-50.6	-14.6	-1.1	-5.9	4.8	48.3	5.6	-21.7	-1.6	−62.3%
2024	-11.5	77.1	-29.4	-20.5	17.2	27.0	-15.9	-9.3	-14.1	-18.9	-0.8	-20.4	−45.1%
2023	10.0	-19.0	10.9	-9.9	-13.0	-21.5	17.4	-13.3	7.0	-8.6	3.0	3.2	−35.6%
2022	-14.8	-24.0	14.2	-28.7	-30.9	8.1	-12.3	-24.2	43.1	-43.9	-81.1	-50.5	−98.0%
2021	-2.5	-16.6	3.0	-18.4	-21.4	18.1	-1.2	25.8	-10.1	-52.4	-9.0	-24.2	−76.8%
2020	4.0	69.2	-9.7	2.2	-7.0	-39.1	-20.4	-5.1	-7.6	-10.7	7.8	-3.0	−40.0%
2019	32.1	23.4	-12.9	7.8	-32.3	-3.6	-22.1	-14.4	-29.3	-4.5	-1.6	-2.5	−56.8%
2018	23.7	-30.9	-4.1	-16.0	13.3	64.4	-28.2	-80.9	47.1	-40.8	-4.1	-30.8	−89.8%
2017	40.3	-14.6	11.8	4.6	-9.8	29.3	64.6	-54.2	-1.5	2.1	-6.4	-12.5	+1.3%
2016									-17.5	-14.0	1.5	-17.7	−40.8%

INSD

Insider Activity · MTVA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 7, 2026	Strickland David GordonDirector	Stock Award(Grant) at price 0.00 per share.	17.2K	—
Jun 7, 2026	Koven Andrew IanDirector	Stock Award(Grant) at price 0.00 per share.	17.2K	—
Jun 7, 2026	Glickman Mark ADirector	Stock Award(Grant) at price 0.00 per share.	17.2K	—
Jun 7, 2026	Groves Jason LDirector	Stock Award(Grant) at price 0.00 per share.	17.2K	—
Jun 7, 2026	Tursi James PatrickDirector	Stock Award(Grant) at price 0.00 per share.	17.2K	—
Jun 7, 2026	Salsbury MichaelDirector	Stock Award(Grant) at price 0.00 per share.	17.2K	—
Jan 22, 2026	Woodworth Marshall HChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	28K	—
Jan 22, 2026	Kim Hyung HeonChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	32K	—
Aug 11, 2025	Woodworth Marshall HChief Financial Officer	Stock Gift at price 0.00 per share.	14.2K	—
Jun 29, 2025	Strickland David GordonDirector	Stock Award(Grant) at price 0.00 per share.	28.1K	—
Jun 29, 2025	Koven Andrew IanDirector	Stock Award(Grant) at price 0.00 per share.	28.1K	—
Jun 29, 2025	Glickman Mark ADirector	Stock Award(Grant) at price 0.00 per share.	28.1K	—
Jun 29, 2025	Groves Jason LDirector	Stock Award(Grant) at price 0.00 per share.	28.1K	—
Jun 29, 2025	Tursi James PatrickDirector	Stock Award(Grant) at price 0.00 per share.	28.1K	—
Jun 29, 2025	Salsbury MichaelDirector	Stock Award(Grant) at price 0.00 per share.	28.1K	—
Jun 3, 2025	Woodworth Marshall HChief Financial Officer	Purchase at price 0.70 per share.	14.2K	$9.94K
May 7, 2025	Dong-A St Co., Ltd.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 0.71 per share.	4.65M	$3.30M

MTVA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

MTVA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About MetaVia Inc.

Seasonality · MTVA

Insider Activity · MTVA

Congress Trades · MTVA

Investors Holding MTVA

Investors Holding MTVA

Congress Trades · MTVA

Insider Activity · MTVA

Seasonality · MTVA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About MetaVia Inc.

Financial Snapshot

Earnings & Dividends

News